Incannex Healthcare Limited has appointed two principal investigators for its IND opening Phase 2/3 clinical trial, investigating IHL-42X for the treatment of obstructive sleep apnoea (OSA). The lead PIs recruited are Dr John D Hudson of FutureSearch Trials of Neurology, Austin, Texas and Dr Russell Rosenberg of Neurotrials Research Inc, Atlanta, Georgia. Site recruitment and selection in the US..
Lixte Biotechnology has enrolled the first patient in a Phase 1b/2 trial of LB-100 and doxorubicin for advanced soft tissue sarcomas. The aim of the study is to find the appropriate dose of LB-100 with a standard dose of doxorubicin, followed by a randomized Phase 2 trial exploring synergy between the two drugs. Lixte hopes that this combination will improve efficacy exhibited by doxorubicin alo..